U.S. markets open in 2 hours 51 minutes
  • S&P Futures

    3,663.00
    +39.75 (+1.10%)
     
  • Dow Futures

    29,979.00
    +350.00 (+1.18%)
     
  • Nasdaq Futures

    12,386.00
    +109.00 (+0.89%)
     
  • Russell 2000 Futures

    1,847.20
    +27.10 (+1.49%)
     
  • Crude Oil

    45.37
    +0.03 (+0.07%)
     
  • Gold

    1,809.40
    +28.50 (+1.60%)
     
  • Silver

    23.44
    +0.85 (+3.77%)
     
  • EUR/USD

    1.1967
    +0.0033 (+0.28%)
     
  • 10-Yr Bond

    0.8440
    0.0000 (0.00%)
     
  • Vix

    20.07
    -0.77 (-3.69%)
     
  • GBP/USD

    1.3335
    +0.0003 (+0.03%)
     
  • USD/JPY

    104.4200
    +0.0960 (+0.09%)
     
  • BTC-USD

    19,336.88
    -62.89 (-0.32%)
     
  • CMC Crypto 200

    380.34
    +15.74 (+4.32%)
     
  • FTSE 100

    6,390.45
    +124.26 (+1.98%)
     
  • Nikkei 225

    26,787.54
    +353.92 (+1.34%)
     

Avivagen Inc. Announces Proposed Extension of Warrants

·4 min read

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) ("Avivagen" or the "Corporation"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it will be requesting approval from the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common shares at $1.20 per share, which were originally issued on November 30, 2017. These warrants currently have an expiration date of November 30, 2020. Subject to TSX Venture Exchange approval, the new date of expiry for such warrants will be June 30, 2021. All other terms of such warrants will remain unchanged.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture and OTCQB® Venture Market exchanges under the symbols VIV and VIVXF, and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Australia, Malaysia, Mexico & Brazil.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "aim", "anticipate", "appear", "believe", "consider", "could", "estimate", "expect", "if", "intend", "goal", "hope", "likely", "may", "plan", "possibly", "potentially", "pursue", "seem", "should", "whether", "will", "would" and similar expressions. Statements set out in this news release relating to the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as growth promoters and the proposed warrant extension are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics as growth promoters in livestock feeds due to many factors, many of which are outside of Avivagen’s control. The warrant extension is conditional on TSX Venture Exchange approval and the agreement of Computershare Trust Company of Canada which acts as Warrant Agent for such warrants, both of which are outside of Avivagen’s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2020 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201113005685/en/

Contacts

Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head
Office Phone: 613-949-8164
Website: www.avivagen.com